# **US Zika Pregnancy Registry**Healthcare Providers: How to Register Patients





Zika virus infection during pregnancy has been linked to adverse outcomes including pregnancy loss and microcephaly, absent or poorly developed brain structures, defects of the eye and impaired growth in fetuses and infants. Despite these observations, very little is known about the risks of Zika virus infection during pregnancy. Information about the timing, absolute risk, and spectrum of outcomes associated with Zika virus infection during pregnancy is needed to direct public health action related to Zika virus and guide testing, evaluation, and management.

# **US Zika Pregnancy Registry**

To understand more about Zika virus infection, CDC established the US Zika Pregnancy Registry and is collaborating with state, tribal, local, and territorial health departments to collect information about Zika virus infection during pregnancy and congenital Zika virus infection. The data collected through this registry will be used to update recommendations for clinical care, to plan for services for pregnant women and families affected by Zika virus, and to improve prevention of Zika virus infection during pregnancy.

## **How to Participate**

CDC and state, tribal, local, and territorial health departments request that healthcare providers participate in the US Zika Pregnancy Registry by:

- 1. Reporting cases of pregnant women with laboratory evidence of Zika virus to their state, tribal, local, or territorial health department.
- 2. Collecting pertinent clinical information about pregnant women and their infants on the Pregnancy and Zika Virus Disease Surveillance forms.
- 3. Providing the information to state, tribal, local or territorial health departments or directly to CDC Registry staff if asked to do so by local health officials.
- 4. Notifying state, tribal, local, or territorial health department staff or CDC registry staff of adverse events (e.g., spontaneous abortion, termination of pregnancy).

## Who to Report to the Registry

Healthcare providers should report <u>eligible cases</u> to the health department in accordance with applicable state, tribal, local and territorial laws. Cases of Zika virus infection among pregnant women in the United States with laboratory evidence of Zika virus infection (positive or inconclusive test results, regardless of whether they have symptoms) and infants born to these women, including infants with congenital Zika virus infection, are eligible for inclusion in the registry.

Healthcare providers practicing in Puerto Rico should report eligible cases to the Puerto Rico Zika Active Pregnancy Surveillance System (ZAPSS) rather than to the US Pregnancy Registry.\*

\*Puerto Rico is establishing a separate Zika Active Pregnancy Surveillance System (ZAPSS)



# **How To Report to the Registry**

- Healthcare providers should contact their state, tribal, local, or territorial health department to arrange
  for laboratory testing for Zika virus infection in pregnant women and infants who meet the clinical
  criteria for testing as outlined in the <a href="CDC guidelines">CDC guidelines</a>.
- Through national surveillance of arboviral diseases, CDC may learn about pregnant women and infants with laboratory evidence of Zika virus infection. Healthcare providers can also contact the CDC Zika Pregnancy hotline (available through the EOC Watch Desk at 770-488-7100, <u>ZikaMCH@cdc.gov</u> or <u>ZikaPregnancy@cdc.gov</u> or fax 404-718-2200) to discuss women with laboratory evidence of Zika virus infection. If cases of Zika virus infection are reported by healthcare providers to CDC, registry staff will ensure that state, tribal, local, or territorial health departments are notified.

#### **How the Data are Collected**

Depending on the preference of the state, tribal, local, or territorial health department, either health department staff or CDC Registry staff will contact healthcare providers caring for pregnant women and their infants for data collection.

#### Time points for data collection

Initial Identification of case 2<sup>nd</sup> and 3<sup>rd</sup> trimester At delivery

Infant: Months 2, 6, and 12

CDC is requesting the collection of clinical information in identifiable form as a public health authority, defined in the Health Insurance Portability and Accountability Act (HIPAA) and its implementing regulations, Standards for Privacy of Individually Identifiable Health Information (45 CFR § 164.501) ("Privacy Rule"\*\*). Data to be collected include clinical information pertaining to the pregnant woman's health, monitoring, and testing during pregnancy, results from evaluation and testing conducted at birth, and clinical/developmental information from the infant through the first year of life.

#### More Information about Zika

For more information or to contact CDC Registry staff, call the CDC Emergency Operations Center watch desk at 770-488-7100 and ask for the Zika Pregnancy Hotline or email <a href="mailto:ZikaPregnancy@cdc.gov">ZikaPregnancy@cdc.gov</a>. More information on caring for pregnant women, infants, or children with Zika virus infection is available at <a href="http://www.cdc.gov/zika">http://www.cdc.gov/zika</a>.

#### **CDC Guidance Materials**

- Interim Guidelines for Health Care Providers Caring for Pregnant Women and Women of Reproductive Age with Possible Zika Virus Exposure – United States, 2016 (Feb. 5, 2016) <a href="http://www.cdc.gov/mmwr/volumes/65/wr/mm6505e2.htm">http://www.cdc.gov/mmwr/volumes/65/wr/mm6505e2.htm</a>
- 2. Interim Guidelines for Healthcare Providers Caring for Infants and Children with Possible Zika Virus Infection United States, February 2016 (Feb. 19, 2016) <a href="http://www.cdc.gov/mmwr/volumes/65/wr/mm6507e1.htm">http://www.cdc.gov/mmwr/volumes/65/wr/mm6507e1.htm</a>
- 3. Zika Virus: Collection and Submission of Fetal Tissues for Zika Virus Testing <a href="http://www.cdc.gov/zika/hc-providers/tissue-collection-submission.html">http://www.cdc.gov/zika/hc-providers/tissue-collection-submission.html</a>
- Collection and Submission of Body Fluids for Zika Virus Testing http://www.cdc.gov/zika/hc-providers/body-fluids-collection-submission.html

\*\*Pursuant to 45 CFR § 164.512(b) of the Privacy Rule, covered entities including health plans, health care clearinghouses, and health care providers may disclose, without individual authorization, protected health information to public health authorities\* "...authorized by law to collect or receive such information for the purpose of preventing or controlling disease, injury, or disability, including, but not limited to, the reporting of disease, injury, vital events such as birth or death, and the conduct of public health surveillance, public health investigations, and public health interventions...." CDC is requesting these records as a public health authority conducting a public health activity as described by 45 CFR § 164.512(b), and as authorized by section 301 of the Public Health Service Act. The information requested represents the minimum necessary to carry out the public health purposes of this project pursuant to 45 CFR § 164.514(d) of the Privacy Rule.